Daito Pharmaceutical Co.,Ltd.

Tokyo Stock Exchange 4577.T

Daito Pharmaceutical Co.,Ltd. Receivables for the year ending May 31, 2024: USD 98.14 M

Daito Pharmaceutical Co.,Ltd. Receivables is USD 98.14 M for the year ending May 31, 2024, a -22.53% change year over year. Receivables are the amounts owed to the company by customers for goods sold or services rendered.

Daito Pharmaceutical Co.,Ltd. Receivables for the year ending May 31, 2023 was USD 126.69 M, a 1.02% change year over year.
Daito Pharmaceutical Co.,Ltd. Receivables for the year ending May 31, 2022 was USD 125.41 M, a 7.45% change year over year.
Daito Pharmaceutical Co.,Ltd. Receivables for the year ending May 31, 2021 was USD 116.71 M, a -18.93% change year over year.
Daito Pharmaceutical Co.,Ltd. Receivables for the year ending May 31, 2020 was USD 143.96 M, a 28.18% change year over year.

Key data

Date	Receivables	Inventory	Goodwill	Total Assets

Tokyo Stock Exchange: 4577.T

Daito Pharmaceutical Co.,Ltd.

CEO	Hiroshi Matsumori
IPO Date	March 24, 2010
Location	Japan
Headquarters	326, Yokamachi
Employees	1,070
Sector	Healthcare
Industries Pharmaceuticals Automotive Parts Cleaning Supplies Consumer Packaged Goods Cosmetics Drugstores & Retail Pharmacies Eyewear Personal Care

Description

Daito Pharmaceutical Co.,Ltd. manufactures and sells pharmaceutical products worldwide. The company offers various active pharmaceutical ingredients and intermediates, prescription drugs, OTC drugs, and home-delivery medicines; formulations in various forms, such as tablets, capsules, troches, granules, and powders; and contract manufacturing services for formulations of medicinal products to pharmaceutical companies. It also sells health food products. The company was formerly known as Daito Corporation and changed its name to Daito Pharmaceutical Co.,Ltd. in 1992. Daito Pharmaceutical Co.,Ltd. was incorporated in 1942 and is headquartered in Toyama, Japan.

Key trends

Past 5 years